Insilico Medicine

Upcoming Webinar Announcement 📢 IMGAIA: How AI Can Help Researchers Without a doubt AI is getting powerful. But how can we make it helpful？ At Insilico Medicine, we are committed to developing breakthrough products powered by #generativeAI and applying them to all aspects of life sciences to accelerate drug discovery, empower anti-aging research and support sustainable development. On July 23, 2pm EDT in a Virtual Launch Event, Insilico is going to unveil three innovative in-house developed #AI products for researchers and introduce the updates of Pharma.AI, its proprietary generative AI driven platform for early drug research. In addition, Insilico will introduce the advanced sustainable initiative driven by AI. √ PandaOmics Box, an AI-powered converged research platform, for localized biological research in target identification, #biomarker discovery and indication prioritization. √ DORA, an advanced large language model-driven AI assistant, designed to streamline the process of drafting #academic papers and other related documents. √ Precious-3 GPT, a transformer-based #LLM engine across multi-modal, multi-omics, multi-species for biomedical research through omics data generation and interpretation. Together, we're exploring how AI can help #lifescience researchers accomplish all their tasks more easily and efficiently. During the webinar you'll be able to get FREE access to DORA, the LLM-based paper writing assistant. We look forward to seeing you "virtually" soon! For the detailed agenda, please visit: https://lnkd.in/eVH6nGmd

📹 Your daily update from Science42: DORA! How the #sharedmemory feature enhances the quality of the generation. For more information, please visit: https://lnkd.in/dEPshUTw #datacollection #DORA

The latest from Biospace: Announcing #Sustainability Benchmarking Initiative and New Gen-AI Features of #Pharma.AI Platform Insilico Medicine (“Insilico”), a clinical-stage generative #artificialintelligence (AI)-driven #drugdiscovery company, hosted the recent Insilico Medicine Generative AI Action (IMGAIA) webinar. The webinar featured opening remarks by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. During the virtual event, Alex Aliper, PhD, co-founder and president of Insilico Medicine, announced the company’s sustainability initiative. Following this, the session on product launches and updates was delivered by key AI project leaders. Read the full release here: https://bit.ly/3WmVca1

Thank you to Brian K. Buntz for testing out Science42: #DORA and #Precious3GPT. Check out the full review here: https://lnkd.in/eU-nHuFC

Insilico Medicine Unveils AI Assistant for Medical Research Drafting Insilico's founder and CEO, Alex Zhavoronkov, emphasized the goal of enabling #researchers who may lack the same level of support as those in top-tier institutions. For example, #medicalprofessionals who have limited time for research can use Science42: DORA to formulate and annotate hypotheses, thus unlocking their knowledge through #publications or blog posts. DORA differs from other #generativeAI programs by not providing instant output. Instead, it integrates multiple #LLMs and hundreds of interconnected agents, going through several cycles of reinforcement learning and referencing to generate a draft. This method emphasizes accuracy, although human proofreading remains essential. Read the full report here: https://lnkd.in/dxFFaf6N

Exciting news from yesterday’s press webinar by Insilico Medicine! The company introduced two state of the art generative models, DORA and Precious-3 GPT 🚀 The first one is DORA is a state-of-the-art AI assistant designed to transform the drafting of medical research papers, case studies, and grant applications. DORA harnesses the power of multiple AI and large language models (LLMs) to assist researchers, particularly early-career professionals and non-native English speakers. Unlike traditional generative AI, DORA doesn’t provide instant outputs. Instead, it integrates reinforcement learning and hundreds of interconnected agents, ensuring a thorough, multi-step referencing process. This aims for high accuracy and contextual relevance, though Insilico Medicine notes that human proofreading is still essential for the final draft. Why DORA? The goal is to democratize research support. By providing a sophisticated digital assistant, DORA enables medical professionals with limited research time or institutional backing to effectively formulate and annotate hypotheses, turning their insights into publications and blog posts. 🚀 The second tool, Precious-3 GPT, is an open-source gen AI model for aging research. Precious-3 GPT is a multimodal system targeting aging and related diseases, which ingests clinical data, including compound structures, DNA, and omics-based test results, as well as text-based reports and published research. It then predicts drug sensitivity and cellular interactions while considering the molecular aspects of aging. Why Precious-3 GPT? The aim is to uncover relationships between preclinical models and humans, facilitating advanced research on aging and diseases like osteoarthritis. Researchers can query targets implicated in aging across different species, fostering a deeper understanding and innovative approaches in biomedical research. Try the new open source tools on Discord or Hugging Face (links in the comments) Ever since I backed Insilico Medicine in 2016, It’s never been a lack of innovation coming from the company on a regular basis! Not only did they become a leading AI in drug discovery company with a robust clinical pipeline, but the team is also constantly introducing novel tools for the research community. I really like startup teams with a strong culture of innovation, but also focused on achieving practical results. That’s the type of companies I am ready to support as a business angel or via our VC funds: LongeVC for the longevity and biotech sector, and AniVC for the pets industry, respectively. Reach out if you have bold ideas and you are ready to execute on those ideas! Kudos Alex Zhavoronkov Alex Aliper and Insilico team!💫 #genAI #generativeAI #biotech #entrepreneurship Image credit: Insilico Medicine

#Precious3GPT allows several strategies to identify such compounds, among which we selected the method that relies on generating differential gene lists for younger and older adults. Previous works that have used #machinelearning to identify novel senolytics have reported a 14% (3 out of 21) hit rate 1. In comparison, 23% of the compounds proposed by Precious3GPT showed senomorphic activity and no cytotoxicity. Head over to https://lnkd.in/eCEBzqHf to learn more. #agingresearch #drugdiscovery

📣 IMGAIA begins today at 2pm EST. We hope to see you there. There is still time to register 👉🏼 https://lnkd.in/eVH6nGmd #IMGAIA #GenerativeAI #PharmaAI #sustainability

“I am excited about the clinical progress in this program,” Feng Ren, PhD, co-CEO and chief scientific officer at Insilico, said in a company press release, adding that it “marks a step forward in the validation of AI-driven #drugdiscovery and development. “We look forward to sharing more clinical data and evaluating INS018_055 in a proof-of-concept study soon,” Ren added. Read the full article here: https://lnkd.in/ebDdEvdz #IPF #proofofconcept #orphandrugs

We are proud to announce the following short course and live presentations, led by Petrina Kamya, Ph.D. Kamya, PhD, President of Insilico Medicine Canada, Global Head of AI Platforms, Insilico Medicine, part of Cambridge Healthtech Institute's Discovery on Target 2024 in Boston. -SC9: Fundamentals of #GenerativeAI for Drug Discovery -AI/ML-Enabled Drug Discovery – Part 2 -#TargetIdentification Strategies Discovery on Target highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. We hope to see you this fall in Boston! https://bit.ly/4cN8rb2 #BostonDOT24 #TargetIdentification #DrugDiscovery #BiologicsEvents